CD16A binding proteins and use for the treatment of immune disorders
US7351803B2 · kind B2 · utility
57Cited by
22References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 29, 2003 |
| Grant date | Apr 1, 2008 |
| Priority date | — |
| Expiry date | May 16, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/732
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
CD16A binding proteins useful for the reduction of a deleterious immune response are described. In one aspect, humanized anti-CD16A antibodies, optionally lacking effector function, are used for treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.